These findings not only improve our understanding of the mechanisms behind p53 inactivation in HCC (independent of genetic mutations), but also provide a promising avenue for HCC therapy by targeting hard-to-target p53. The gene discussed is TP53; the disease is hepatocellular carcinoma.